Accéder au contenu
Merck

Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.

Nature communications (2014-10-04)
Cecilia S Leung, Tsz-Lun Yeung, Kay-Pong Yip, Sunila Pradeep, Lavanya Balasubramanian, Jinsong Liu, Kwong-Kwok Wong, Lingegowda S Mangala, Guillermo N Armaiz-Pena, Gabriel Lopez-Berestein, Anil K Sood, Michael J Birrer, Samuel C Mok
RÉSUMÉ

Ovarian cancer is the most lethal gynaecologic malignancy in the United States, and advanced serous ovarian adenocarcinoma is responsible for most ovarian cancer deaths. However, the stroma-derived molecular determinants that modulate patient survival are yet to be characterized. Here we identify a stromal gene signature for advanced high-grade serous ovarian cancer using microdissected stromal ovarian tumour samples and find that stromal microfibrillar-associated protein 5 (MFAP5) is a prognostic marker for poor survival. Further functional studies reveal that FAK/CREB/TNNC1 signalling pathways mediate the effect of MFAP5 on ovarian cancer cell motility and invasion potential. Targeting stromal MFAP5 using MFAP5-specific siRNA encapsulated in chitosan nanoparticles significantly decreases ovarian tumour growth and metastasis in vivo, suggesting that it may be a new modality of ovarian cancer treatment.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-intégrine αVβ3, clone LM609, sans azoture, clone LM609, Chemicon®, from mouse
Sigma-Aldrich
SU 6656, ≥98% (HPLC)
Sigma-Aldrich
Anti-MFAP5 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-TNNC1 antibody produced in mouse, clone 1F8-A9, purified immunoglobulin, buffered aqueous solution